Leukotriene Receptor Antagonists Pranlukast and Montelukast for Treating Asthma

Expert Opinion on Pharmacotherapy - United Kingdom
doi 10.1517/14656566.2014.872241
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa Healthcare

Related search

Bronchoprotective Effects of Leukotriene Receptor Antagonists in Asthma

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2002English

Leukotriene Receptor Antagonists and Biosynthesis Inhibitors: Potential Breakthrough in Asthma Therapy

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
1995English

Churg-Strauss Vasculitis Syndrome and Leukotriene Receptor Antagonists

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2005English

Acute Interstitial Pneumonia Induced by ONO-1078 (Pranlukast), a Leukotriene Receptor Antagonist.

Internal Medicine
Internal MedicineMedicine
2001English

Inhaled Glucocorticoids Versus Leukotriene Receptor Antagonists as Single Agent Asthma Treatment: Systematic Review of Current Evidence

BMJ
2003English

Evening Dosing Is Associated With Higher Plasma Concentrations of Pranlukast, a Leukotriene Receptor Antagonist, in Healthy Male Volunteers

British Journal of Clinical Pharmacology
Pharmacology
2003English

Role of Leukotriene Receptor Antagonists in the Treatment of Exercise-Induced Bronchoconstriction: A Review

Allergy, Asthma and Clinical Immunology
ImmunologyPulmonaryAllergyRespiratory Medicine
2005English

Leukotriene Antagonists and Churg-Strauss Syndrome: The Smoking Gun

Thorax
PulmonaryRespiratory Medicine
1999English

Treating Asthma.

BMJ
1971English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy